Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 12, 2017

Primary Completion Date

April 28, 2023

Study Completion Date

May 31, 2023

Conditions
Congestive Heart FailureHeart Failure, Diastolic
Interventions
BIOLOGICAL

Allogeneic Derived Cells

patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.

BIOLOGICAL

Placebo/Control Arm

patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.

Trial Locations (1)

29425

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

lead

Cedars-Sinai Medical Center

OTHER

NCT02941705 - Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs | Biotech Hunter | Biotech Hunter